Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Rotella, Carlo M ^a   Zaninelli, Augusto ^a   Le Grazie, Cristina ^b   Hanson, Mary E ^c   Gensini, Gian Franco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Medical Affairs and Scientific Relations   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; MIDDLE AGED; RISK FACTOR; STATISTICS;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; SIMVASTATIN; STATISTICS AS TOPIC;

EID: 77954873703     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-80     Document Type: Article

References (38)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert panel on detection evaluation and treatment of high blood cholesterol in adults, JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
2. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). I Graham D Atar K Borch-Johnsen G Boysen G Burell R Cifkova J Dallongeville G De Backer S Ebrahim B Gjelsvik C Herrmann-Lingen A Hoes S Humphries M Knapton J Perk SG Priori K Pyorala Z Reiner L Ruilope S Sans-Menendez WS Op Reimer P Weissberg D Wood J Yarnell JL Zamorano E Walma T Fitzgerald MT Cooney A Dudina A Vahanian, et al. Eur J Cardiovasc Prev Rehabil 2007 14 Suppl 2 1 113 10.1097/01.hjr.0000277983.23934.c9 17726407
3. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 91 Suppl 5 &221 52 16365341
4. -2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. J Genest R McPherson J Frohlich T Anderson N Campbell A Carpentier P Couture R Dufour G Fodor GA Francis S Grover M Gupta RA Hegele DC Lau L Leiter GF Lewis E Lonn GB Mancini D Ng GJ Pearson A Sniderman JA Stone E Ur, Can J Cardiol 2009 25 567 579 19812802
5. Statin therapy: where are we? Where do we go next? AM Gotto Jr, Am J Cardiol 2001 87 13B 18B 10.1016/S0002-9149(01)01450-3 11256844
6. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. HR Davis EP Veltri, J Atheroscler Thromb 2007 14 99 108 17587760
7. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. CA Dujovne MP Ettinger JF McNeer LJ Lipka AP LeBeaut R Suresh B Yang EP Veltri, Am J Cardiol 2002 90 1092 1097 10.1016/S0002-9149(02)02798-4 12423709
8. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. RH Knopp H Gitter T Truitt H Bays CV Manion LJ Lipka AP LeBeaut R Suresh B Yang EP Veltri, Eur Heart J 2003 24 729 741 10.1016/S0195-668X(02)00807-2 12713767
9. Ezetimibe: cholesterol lowering and beyond. HE Bays D Neff JE Tomassini AM Tershakovec, Expert Rev Cardiovasc Ther 2008 6 447 470 10.1586/14779072.6.4. 447 18402536
10. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). CM Ballantyne R Weiss T Moccetti A Vogt B Eber F Sosef E Duffield, Am J Cardiol 2007 99 673 680 10.1016/j.amjcard.2006.10.022 17317370
11. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. SE Conard HE Bays LA Leiter SR Bird J Rubino RS Lowe JE Tomassini AM Tershakovec, Am J Cardiol 2008 102 1489 1494 10.1016/j.amjcard.2008.09.075 19026302
12. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. LA Leiter H Bays S Conard S Bird J Rubino ME Hanson JE Tomassini AM Tershakovec, Am J Cardiol 2008 102 1495 1501 10.1016/j.amjcard.2008.09.076 19026303
13. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. JG Robinson M Davidson A Shah J Lin D Neff P DeLucca JE Tomassini E Veltri AM Tershakovec, Aging Health 2007 3 691 705 10.2217/1745509X.3.6.691
14. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. RB Goldberg JR Guyton T Mazzone RS Weinstock A Polis P Edwards JE Tomassini AM Tershakovec, Mayo Clin Proc 2006 81 1579 1588 10.4065/81.12.1579 17165637
15. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. LM Gaudiani A Lewin L Meneghini I Perevozskaya D Plotkin Y Mitchel S Shah, Diabetes Obes Metab 2005 7 88 97 10.1111/j.1463-1326.2004.00420.x 15642080
16. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. C Constance S Westphal N Chung M Lund SC McCrary AO Johnson-Levonas R Massaad C Allen, Diabetes Obes Metab 2007 9 575 584 10.1111/j.1463-1326.2007.00725.x 17451425
17. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). G Bardini CB Giorda AE Pontiroli C Le Grazie CM Rotella, Cardiovasc Diabetol 2010 9 20 10.1186/1475-2840-9-20 20492655
18. Ezetimibe/simvastatin compared with doubling the dose of simvastatin in high cardiovascular risk patients not at LDL-C target with simvastatin alone: the DIALOGUE study [abstract]. M Averna A Zaninelli C Le Grazie GF Genisini, Nutrition Metabolism and Cardiovascular Diseases 2009 19 1 S2 10.1016/S0939-4753(09)70005-5
19. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. CM Ballantyne N Abate Z Yuan TR King J Palmisano, Am Heart J 2005 149 464 473 10.1016/j.ahj.2004.11.023 15864235
20. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. M Farnier M Averna L Missault H Vaverkova M Viigimaa R Massaad K Vandormael AO Johnson-Levonas P Brudi, Int J Clin Pract 2009 63 547 559 10.1111/j.1742-1241. 2009.02022.x 19222610
21. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. SK Hildemann C Barho B Karmann H Darius K Bestehorn, Curr Med Res Opin 2007 23 713 719 10.1185/030079907X178702 17407627
22. Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study. KK Lee VW Lee WK Chan BS Lee AC Chong JC Wong D Yin E Alemao B Tomlinson, Value Health 2008 11 Suppl 1 91 S98 10.1111/j.1524-4733.2008.00372.x 18387073
23. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. JS Schultz JC O'Donnell KL McDonough R Sasane J Meyer, Am J Manag Care 2005 11 306 312 15898219
24. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. TG Allison RW Squires BD Johnson GT Gau, Mayo Clin Proc 1999 74 466 473 10.4065/74.5.466 10319076
25. The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population. PH Chong PJ Tzallas-Pontikes JD Seeger TD Stamos, Pharmacotherapy 2000 20 1454 1463 10.1592/phco.20.19.1454.34855 11130218
26. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. HW van Lennep Roeters AH Liem PH Dunselman GM Dallinga-Thie AH Zwinderman JW Jukema, Curr Med Res Opin 2008 24 685 694 10.1185/030079908X273273 18226326
27. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. M Denke T Pearson P McBride RA Gazzara WE Brady AM Tershakovec, Diab Vasc Dis Res 2006 3 93 102 10.3132/dvdr.2006.020 17058629
28. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. L Simons M Tonkon L Masana D Maccubbin A Shah M Lee B Gumbiner, Curr Med Res Opin 2004 20 1437 1445 10.1185/030079904X2321 15383192
29. Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared with Rosuvastatin 10 mg in High-Risk Patients with and Without Type 2 Diabetes Mellitus (T2DM) [abstract]. P Brudi M Vaverkova M Averna M Viigimaa Q Dong A Shah AO Johnson-Levonas L Missault, J Clin Lipidology 2009 3 233 10.1016/j.jacl.2009.04.042
30. Perspectives on low-density lipoprotein cholesterol goal achievement. AL Catapano, Curr Med Res Opin 2009 25 431 447 10.1185/03007990802631438 19192988
31. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. TM van Himbergen NR Matthan NA Resteghini S Otokozawa M Ai EA Stein PH Jones EJ Schaefer, J Lipid Res 2009 50 730 739 10.1194/jlr.P800042-JLR200 19043140
32. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. L Pisciotta T Fasano A Bellocchio L Bocchi R Sallo R Fresa I Colangeli A Cantafora S Calandra S Bertolini, Atherosclerosis 2007 194 116 e122 10.1016/j.atherosclerosis.2006.10.036 17140581
33. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. H Gylling TA Miettinen, Atherosclerosis 1996 126 325 332 10.1016/0021-9150(96)05930-8 8902158
34. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. SE Lally D Owens GH Tomkin, Diabetologia 2007 50 217 219 10.1007/s00125-006-0504-0 17102949
35. Alterations in cholesterol absorption and synthesis characterize Framingham offspring study participants with coronary heart disease. NR Matthan M Pencina JM Larocque PF Jacques RB D'Agostino EJ Schaefer AH Lichtenstein, J Lipid Res 2009 1927 1935 10.1194/jlr.P900039-JLR200 19436064
36. Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. EM Ooi TW Ng DC Chan GF Watts, Diabetes Res Clin Pract 2009 85 310 316 10.1016/j.diabres.2009.06.003 19573945
37. Diabetes contributes to cholesterol metabolism regardless of obesity. PP Simonen HK Gylling TA Miettinen, Diabetes Care 2002 25 1511 1515 10.2337/diacare.25.9.1511 12196419
38. The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. P Simonen H Gylling TA Miettinen, Atherosclerosis 2008 197 883 888 10.1016/j. atherosclerosis.2007.08.003 17875306